Preclinical Characterization of PC786, an Inhaled Small-Molecule Respiratory Syncytial Virus L Protein Polymerase Inhibitor

Matthew Coates, Daniel Brookes, Young-In Kim, Heather Allen, Euan A. F. Fordyce, Elizabeth A. Meals, Thomas Colley, Claire-Lise Ciana, Guillaume F. Parra, Vladimir Sherbukhin, Jennifer A. Stockwell, Jennifer C. Thomas, S. Fraser Hunt, Lauren Anderson-Dring, Stuart T. Onions, Lindsey Cass, Peter J. Murray, Kazuhiro Ito, Pete Strong, John P. DeVincenzo, Garth Rapeport
  • Antimicrobial Agents and Chemotherapy, June 2017, ASM Journals
  • DOI: 10.1128/aac.00737-17

A novel inhaled RSV polymerase inhibitor, PC786, on RSV infection

What is it about?

Although respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants and young children, attempts to develop an effective therapy have so far proved unsuccessful. Herein we report the preclinical profiles of PC786, a potent non-nucleoside RSV L-protein polymerase inhibitor, designed for inhalation treatment of RSV infection.

Why is it important?

Effective anti-respiratory syncytial virus (RSV) agents are still not available for clinical use. Current major targets are virus surface proteins, such as a fusion-protein involved in viral entry, but agents effective after RSV infection is established are required. PC786 demonstrated potent anti-RSV effects on recent clinical isolates and also the anti-viral activity of PC786 were largely unaffected by the amount of virus particles infected and retained in the face of established RSV replication in a time-of-addition study . Thus, PC786 has the potential to be an effective therapeutic agent to treat active RSV infection.

The following have contributed to this page: Kazuhiro Ito